With the imminent emergence of personalized medicine and the availability of costly targeted drugs comes the crucial allocation of ressources within the halthcare systems. Determining which treatment options should be funded has become an increasingly difficult task. Decision-makers are relying heavily on pharmacoeconomic (PE) evalutions to decide which of them will be most effective and […]
Read More